Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Revance Therapeutics Inc. maintains 5 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners, showing that most pending matters are assigned to different individuals. The prosecution activity is concentrated within 3 distinct art units, reflecting a relatively focused technical scope for these specific pending applications compared to the number of examiners involved. This concentration in 3 distinct art units suggests a thematic consistency in the company's current filings.
SWIFT, CANDICE LEE serves as the busiest examiner for the company, overseeing 2 pending office actions. This concentration represents the only instance where an examiner manages multiple pending office actions. With 4 distinct examiners involved, the company must tailor its responses to individual perspectives while operating across the 3 distinct art units identified in the data. The presence of 5 pending office actions across 4 distinct examiners indicates that the workload is distributed among most of the involved officials.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 2 | 57.5% | +36.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| DUTT, ADITI | 1 | 47.0% | +48.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278169 | METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY | SWIFT, CANDICE LEE | 47d |
| 17912513 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | SWIFT, CANDICE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18414311 | Albumin-Free Botulinum Toxin Formulations | OGUNBIYI, OLUWATOSIN A | 26d |
| 18278169 | METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY | SWIFT, CANDICE LEE | 47d |
| 17951220 | INJECTABLE BOTULINUM TOXIN FORMULATIONS | JACKSON-TONGUE, LAKIA J | — |
| 17912513 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | SWIFT, CANDICE LEE | — |
| 17135938 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect | DUTT, ADITI | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| 1657 | 2 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18414311 | Albumin-Free Botulinum Toxin Formulations | OGUNBIYI, OLUWATOSIN A | 1645 | §102 | Non-Final OA | 26d | Pending | Jan 16, 2024 |
| 18278169 | METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY | SWIFT, CANDICE LEE | 1657 | §103§112Other | Final Rejection | 47d | Pending | Aug 21, 2023 |
| 17951220 | INJECTABLE BOTULINUM TOXIN FORMULATIONS | JACKSON-TONGUE, LAKIA J | 1645 | §102 | Final Rejection | — | Pending | Sep 23, 2022 |
| 17912513 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | SWIFT, CANDICE LEE | 1657 | §103§112Other | Non-Final OA | — | Pending | Sep 18, 2022 |
| 17135938 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect | DUTT, ADITI | 1675 | §103DP | Non-Final OA | — | Pending | Dec 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial